Literature DB >> 9558335

An AP-1 site in the nerve growth factor promoter is essential for 1, 25-dihydroxyvitamin D3-mediated nerve growth factor expression in osteoblasts.

T D Veenstra1, M Fahnestock, R Kumar.   

Abstract

1,25-Dihydroxyvitamin D3 (1,25(OH)2D3), the active metabolite of vitamin D, induces nerve growth factor (NGF) synthesis in a variety of different cell lines. The mechanism by which 1,25(OH)2D3 induces NGF, however, is poorly understood. We used a series of full-length and truncated NGF promoter-human growth hormone (hGH) reporter gene plasmids to investigate the mechanism of 1,25(OH)2D3-induced NGF expression in osteoblasts. Untransfected rat osteosarcoma cells (ROS 17/2.8) treated with 1,25(OH)2D3 showed a 2-fold increase in NGF expression compared to control cells. ROS 17/2.8 osteosarcoma cells were transfected with the NGF-hGH reporter plasmids and treated with 10(-)8 M 1,25(OH)2D3. The full-length NGF promoter (-1800 to +120)-hGH reporter construct showed an approximately 2-fold increase in hGH release. Plasmids with successive 5'-deletions showed enhanced hGH expression in treated cells and control cells. A similar series of NGF promoter-hGH reporter gene constructs, lacking the AP-1 site located within the first intron of the NGF gene, were also transiently transfected into ROS 17/2.8 cells. When these cells were treated with the same dose of 1,25(OH)2D3, no increase in hGH expression was seen compared to control cells, demonstrating that this AP-1 site is essential for 1,25(OH)2D3-mediated NGF up-regulation. Since 1,25(OH)2D3 is known to activate the transcription of several genes through its interaction with the vitamin D receptor (VDR), we performed a series of gel electrophoretic mobility shift assays to determine if the VDR binds directly to the AP-1 sequence. No evidence of VDR binding, either as a homodimer or as a heterodimer, to the AP-1 sequence was observed. Treatment of ROS 17/2.8 cells with 1,25(OH)2D3, however, resulted in an increase in AP-1 binding activity; however, no significant changes in c-jun and c-fos levels were observed. Our data show that in osteoblasts, 1,25(OH)2D3 induces NGF expression indirectly by increasing AP-1 binding activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9558335     DOI: 10.1021/bi972965+

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

Review 1.  Is bone a target-tissue for the nervous system? New advances on the understanding of their interactions.

Authors:  J M García-Castellano; P Díaz-Herrera; J A Morcuende
Journal:  Iowa Orthop J       Date:  2000

2.  Detection of 1α,25-dihydroxyvitamin D-regulated miRNAs in zebrafish by whole transcriptome sequencing.

Authors:  Theodore A Craig; Yuji Zhang; Andrew T Magis; Cory C Funk; Nathan D Price; Stephen C Ekker; Rajiv Kumar
Journal:  Zebrafish       Date:  2014-03-20       Impact factor: 1.985

3.  Proteasome inhibition by fellutamide B induces nerve growth factor synthesis.

Authors:  John Hines; Michael Groll; Margaret Fahnestock; Craig M Crews
Journal:  Chem Biol       Date:  2008-05

4.  Nerve growth factor promoter activity revealed in mice expressing enhanced green fluorescent protein.

Authors:  Michael D Kawaja; Laura J Smithson; Janet Elliott; Gina Trinh; Anne-Marie Crotty; Bernadeta Michalski; Margaret Fahnestock
Journal:  J Comp Neurol       Date:  2011-09-01       Impact factor: 3.215

5.  Expression and regulation of the vitamin D receptor in the zebrafish, Danio rerio.

Authors:  Theodore A Craig; Stacy Sommer; Caroline R Sussman; Joseph P Grande; Rajiv Kumar
Journal:  J Bone Miner Res       Date:  2008-09       Impact factor: 6.741

6.  Role of vitamin d in Parkinson's disease.

Authors:  Khanh L Ng; Lan Nguyễn
Journal:  ISRN Neurol       Date:  2012-03-07

Review 7.  Vitamin D and Alzheimer's Disease: Neurocognition to Therapeutics.

Authors:  Anindita Banerjee; Vineet Kumar Khemka; Anirban Ganguly; Debashree Roy; Upasana Ganguly; Sasanka Chakrabarti
Journal:  Int J Alzheimers Dis       Date:  2015-08-17

Review 8.  Vitamin D and Neurological Diseases: An Endocrine View.

Authors:  Carolina Di Somma; Elisabetta Scarano; Luigi Barrea; Volha V Zhukouskaya; Silvia Savastano; Chiara Mele; Massimo Scacchi; Gianluca Aimaretti; Annamaria Colao; Paolo Marzullo
Journal:  Int J Mol Sci       Date:  2017-11-21       Impact factor: 5.923

Review 9.  Vitamin D and neurocognitive function.

Authors:  Mathias Schlögl; Michael F Holick
Journal:  Clin Interv Aging       Date:  2014-04-02       Impact factor: 4.458

Review 10.  A Review of the Relationship Between Vitamin D and Parkinson Disease Symptoms.

Authors:  Michelle E Fullard; John E Duda
Journal:  Front Neurol       Date:  2020-05-27       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.